Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) PT at $214.00

Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned a consensus rating of “Hold” from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $214.00.

CRL has been the topic of several research analyst reports. Robert W. Baird cut their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, September 20th. TD Cowen boosted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Finally, Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target for the company.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its holdings in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after buying an additional 3,738,018 shares in the last quarter. State Street Corp boosted its stake in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its position in shares of Charles River Laboratories International by 1.7% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock valued at $394,359,000 after purchasing an additional 31,359 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after buying an additional 509,163 shares during the last quarter. Finally, Earnest Partners LLC increased its position in Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

Shares of CRL opened at $174.37 on Monday. The firm has a 50-day simple moving average of $193.36 and a two-hundred day simple moving average of $199.12. The stock has a market cap of $8.92 billion, a PE ratio of 21.82, a P/E/G ratio of 4.92 and a beta of 1.38. Charles River Laboratories International has a 1-year low of $173.81 and a 1-year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same quarter last year, the firm earned $2.72 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, analysts forecast that Charles River Laboratories International will post 10.18 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).